A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Phase 2TerminatedNCT03029832

Genentech, Inc.5 enrolled

Overview

This is a Phase II, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of MOXR0916 in combination with atezolizumab versus placebo and atezolizumab in participants with locally advanced or metastatic urothelial carcinoma (UC) who have not received prior systemic therapy in the locally advanced/metastatic setting and who are ineligible to receive cisplatin-based therapy.

The study design has been amended after the decision to prematurely stop patient accrual due to enrollment challenges. As only 5 participants were enrolled, the study blinding will not be maintained, and placebo infusions will not be administered. Patients assigned to the MOXR0916 arm may continue study treatment with the combination of atezolizumab and MOXR0916 or with atezolizumab alone based on a discussion of benefit and risk with the treating investigator.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Urothelial Carcinoma

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of \<= 2 * Life expectancy \>= 12 weeks * Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma (UC) * Availability of a representative formalin-fixed paraffin-embedded tumor specimen * No prior systemic therapy for inoperable locally advanced or metastatic UC * Ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria: Impaired renal function (glomerular filtration rate \[GFR\] \> 30 but \< 60 milliliter/minute \[mL/min\]); National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0 Grade \>= 2 audiometric hearing loss (of 25 Decibel at two contiguous frequencies or more severe); NCI CTCAE v 4.0 Grade \>= 2 peripheral neuropathy; ECOG Performance Status of 2 * Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 * Adequate hematologic and end-organ function Exclusion Criteria: * Significant cardiovascular disease * Known clinically significant liver disease * Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment * Prior treatment with CD137 or OX40 agonists, anti-cytotoxic T-lymphocyte-associated protein (CTLA4), anti-programmed death-1 (PD-1), anti- programmed death-ligand 1 (PD-L1), anti-CD-27, anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) therapeutic antibody or pathway-targeting agents * Untreated central nervous system (CNS) metastases or active (progressing or requiring corticosteroids for symptomatic control) CNS metastases * Any history of leptomeningeal disease * Malignancies other than UC within 5 years prior to Cycle 1, Day 1 * History of autoimmune disease * History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan * Active hepatitis B and C virus infection * Positive HIV test at screening * Active tuberculosis * Prior allogeneic stem cell or solid organ transplantation

Locations (22)

Arizona Oncology - HOPE Wilmot

Tucson, Arizona, United States

University of Colorado

Denver, Colorado, United States

Yale University

New Haven, Connecticut, United States

Miami Cancer Institute of Baptist Health, Inc.

Miami, Florida, United States

University of Chicago; Hematology/Oncology

Chicago, Illinois, United States

Kansas City - Menorah Medical Center

Kansas City, Kansas, United States

Maryland Oncology Hematology, P.A.

Columbia, Maryland, United States

Nebraska Methodist Hospital; Cancer Center

Omaha, Nebraska, United States

New York Oncology Hematology, P.C.

Albany, New York, United States

Columbia University Medical Center; Clinical Research Management Office

New York, New York, United States

...and 12 more locations

Outcomes

Primary Outcomes

Progression-Free Survival (PFS)

PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first. Per RECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline); and an absolute increase of \>= 5 millimeter (mm) in the sum of diameters.